Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as higher yields and oil prices flag inflation risk
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
Inovio Pharma (INO) Posts Q3 Loss of 12c/Share; Offers Corp. Update
November 10, 2014 6:48 AM ESTInovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.8 million versus the consensus estimate of $5.6 million.
Corporate Update
Clinical Development
In the third quarter, Inovio released top line efficacy data from its randomized,... More



